



Resonance Health Ltd
ASX / Media Release

23 July 2013

Resonance Health Awarded Phase II Clinical Trial

Resonance Health has been awarded a new two year contract by a large international pharmaceutical company to provide FerriScan services to evaluate a therapy to treat patients with chronic transfusional iron overload.

Resonance Health will be working with approximately 25 MRI facilities across a number of countries. The radiology facilities will be trained by Resonance Health in the FerriScan imaging requirements and will perform the patient MRI scanning during the clinical trial. The image data will be sent from the radiology facilities to Resonance Health's ISO 13485 certified facility in Perth where our trained technicians will analyse the image data utilising the Company's patented FerriScan technology to quantify the liver iron concentration.

There are a variety of diseases that can cause iron overload. Hemoglobinopathies such as thalassemia and sickle cell disease often require repeat blood transfusions which result in the patient accumulating excess iron. An iron chelating drug is required to remove the excess iron.

FerriScan is internationally recognised as the gold standard non-invasive test for assessing liver iron concentration and we see the award of this significant contract as further endorsement of FerriScans' premier position in the commercial market. On the 8th July 2013 we announced the publication of the FerriScan validation paper in the journal Magnetic Resonance in Medicine [[Link to paper](#)]. This publication confirms the robustness of the FerriScan technology across different makes and models of MRI scanners and that it is unaffected by confounding factors such as liver fibrosis.

Resonance Health is delighted that FerriScan has been chosen for this Phase II clinical study on iron overload.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300

E: lizad@resonancehealth.com

Naomi Haydari
Company Secretary
T: +61 8 9286 5300

E: naomih@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.